CD7 targeting UCAR-T cell therapy (PersonGen BioTherapeutics)

CD7 targeted CAR‐T has demonstrated potential in the treatment of T cell malignancies but no study has been reported about its potential in the prophylaxis of GVHD in allo‐HSCT. Here we reported a special case that a boy diagnosed with refractory acute T lymphoblastic leukemia (T‐ALL) was treated with universal CD7 targeted CAR‐T (CD7 UCAR‐T) and parent‐derived peripheral blood stem cells (PBSCs). Complete remission and full engraftment of donor was observed. In the later four months of follow‐up, in the absence of any immunodepression treatment, no signs of GVHD were observed. This case initially demonstrates the potential of CD7 UCAR‐T in the prophylaxis of GVHD.